cap-dependent

Cap-dependent endonuclease-IN-1 is a highly potent and orally active cap-dependent endonuclease inhibitor with antiviral activity for the study of influenza virus infection.

Cap-dependent endonuclease-IN-9 is a potent (CEN) inhibitor with notable efficacy against the influenza virus and exhibits minimal cytotoxicity, enhanced in vivo pharmacokinetics, and robust pharmacodynamics. It effectively suppresses the RNA polymerase activity of A virus[1].

Cap-dependent endonuclease-IN-15 is a potent inhibitor of cap-dependent endonuclease (CEN), effectively hindering the replication of influenza virus. This compound shows promise for the investigation of viral infections triggered by influenza viruses.

Cap-dependent endonuclease-IN-5 is a potent inhibitor of cap-dependent nucleic acid endonucleases (CEN). cap-dependent endonuclease-IN-5 has good influenza virus inhibitory activity and/or has lower cytotoxicity, better in vivo pharmacokinetic properties and in vivo pharmacodynamic properties.

Cap-dependent endonuclease-IN-22 is a powerful inhibitor of cap-dependent endonuclease (CEN) [1].

Cap-dependent endonuclease-IN-8 is a potent inhibitor of cap-dependent nucleic acid endonucleases (CEN). cap-dependent endonuclease-IN-8 inhibits the replication of orthomyxoviruses, including influenza A, B and C.

Cap-dependent endonuclease-IN-7 is a potent inhibitor of cap-dependent endonuclease (CEN), effectively inhibiting viral mRNA synthesis and subsequently halting virus proliferation. This compound is specifically promising for research into viral infections, including influenza types A, B, and C.

Cap-dependent endonuclease-IN-13 is a potent inhibitor of cap-dependent endonuclease (CEN) and shows research potential against influenza virus infection (influenza A only).

Cap-dependent endonuclease-IN-16 is a pyridone polycyclic derivative and a potent inhibitor of cap-dependent nucleic acid endonucleases (CEN). cap-dependent endonuclease-IN-16 shows potential for influenza studies.

Cap-dependent endonuclease-IN-23 is a potent inhibitor of cap-dependent nucleic acid endonucleases (CEN) and has inhibitory effects on influenza virus replication. cap-dependent endonuclease-IN-21 shows research potential for influenza virus infection (influenza A)。

Cap-dependent endonuclease-IN-14 is a potent inhibitor of cap-dependent nucleic acid endonucleases (CEN) and is able to inhibit the replication of influenza viruses. cap-dependent endonuclease-IN-14 shows potential for viral infections caused by influenza viruses.

Cap-dependent endonuclease-IN-21 is a potent inhibitor of cap-dependent nucleic acid endonucleases (CEN) and has inhibitory effects on influenza virus replication. cap-dependent endonuclease-IN-21 has shown research potential against influenza virus infection (influenza A).

Cap-dependent endonuclease-IN-6 (compound 13) is a Cap-dependent endonuclease (CEN) inhibitor that inhibits influenza virus.

Cap-dependent endonuclease-IN-11 is a potent inhibitor of cap-dependent nucleic acid endonucleases (CEN). cap-dependent endonuclease-IN-11 has shown research potential for viral infections.

Cap-dependent endonuclease-IN-3 is a potent inhibitor of cap-dependent nucleic acid endonucleases (CEN). Cap-dependent endonuclease-IN-3 has shown potential for the investigation of influenza A and B infections.

Cap-dependent endonuclease-IN-19 is a spirocyclic pyridinone derivative and a potent inhibitor of cap-dependent nucleic acid endonuclease (CEN). cap-dependent endonuclease-IN-19 potently inhibits the RNA polymerase activity of influenza A virus.

Cap-dependent endonuclease-IN-26, a potent inhibitor of cap-dependent endonuclease (CEN) with an IC50 of 286 nM, exhibits significant antiviral activity against a broad spectrum of influenza A and B strains [1].

Cap-dependent endonuclease-IN-25 is a macrocyclic pyridoxal derivative and a potent inhibitor of cap-dependent nucleic acid endonucleases (CEN). The Cap-dependent endonuclease IN-25 has potential for the study of viral infections caused by viruses of the Orthomyxoviridae family.

Cap-dependent Endonuclease-IN-12 (EXP-35) is a potent inhibitor of Cap-dependent endonuclease, demonstrating low cytotoxicity. This compound exhibits inhibitory effects on H1N1 [1].

Cap-dependent endonuclease-IN-10 is a potent inhibitor of cap-dependent nucleic acid endonucleases (CEN). cap-dependent endonuclease-IN-10 effectively inhibits influenza viruses with low cytotoxicity, good in vivo pharmacokinetic and in vivo pharmacodynamic properties, and good hepatic microsomal stability. Cap-dependent endonuclease-IN-10 has shown investigational potential against viral infections, including influenza A, B and C.

Cap-dependent endonuclease-IN-2 is a potent inhibitor of cap-dependent nucleic acid endonucleases (CEN). Cap-dependent endonuclease-IN-2 significantly inhibits influenza A virus RNA polymerase activity.

Cap-dependent endonuclease-IN-17 is a cap-dependent endonuclease (CEN) inhibitor. cap-dependent endonuclease-IN-17 exhibits antiviral activity (IC50: 1.29 μM) against influenza virus A/Hanfang/359/95 (H3N2).

Baloxavir marboxil (S-033188) is a novel cap-dependent endonuclease inhibitor for the treatment of influenza A and B virus infections.

Baloxavir (S-033447) is a first-in-class cap-dependent endonuclease inhibitor of the influenza virus polymerase PA subunit.

eIF4E-IN-5 (Compound 6n) is a cell-permeable eIF4E inhibitor that binds to capped mRNA, thereby inhibiting cap-dependent translation [1].

Influenza virus-IN-7 (Example 16) is an orally active inhibitor of cap-dependent endonuclease, employed in research on influenza viral infectious diseases [1].

CAP 3 is a cholic acid-peptide conjugate (CAP) with antibacterial activity. It is active against the Gram-negative bacteria E. coli, K. pneumoniae, and A. baumanii (MIC99s = 8, 16, and 16 μM, respectively). CAP 3 increases the fluidity of model Gram-negative bacterial membranes and binds to LPS in vitro. It reduces the biomass and number of colony-forming units in E. coli biofilms in a concentration-dependent manner. CAP 3 inhibits E. coli biofilm formation on catheters implanted in mice infected with E. coli at the incision site when applied as a coating on the catheters. CAP 3 (40 mg/kg) also reduces bacterial load in E. coli-infected wounds in mice. It is cytotoxic to A459 cells (IC50 = 56.4 μM) and has hemolytic activity against human red blood cells with a 50% lysis (HC50) value of 48 μM.

7-Methyl-guanosine-5'-triphosphate (m7GTP) sodium, a guanosine 5'-phosphate derivative, serves as a potent inhibitor of cap-dependent translation, with its sodium phosphorothioate analog enhancing its efficacy [1].

Baloxavir-d4 is a deuterated compound of Baloxavir. Baloxavir has a CAS number of 1985605-59-1. Baloxavir is a first-in-class cap-dependent endonuclease inhibitor of the influenza virus polymerase PA subunit.